Dose of vaccine applied against COVID-19 and recovery of the patient treated in the ICU-COVID. EsSalud-Lambayeque contingency Hospitals. December 2021February 2022

被引:0
|
作者
Monteza, Jose E. Pecsen [1 ,2 ]
Monteza, Valentin A. Pecsen [3 ,4 ]
Paredes, Rolando R. Romero [5 ]
Lent, Fernando M. Carranza [6 ]
机构
[1] EsSalud, Hosp Almanzor Aguinaga Asenjo, Serv Nefrol, Chiclayo, Peru
[2] Univ Nacl Pedro Ruiz Gallo, Lambayeque, Peru
[3] EsSalud, Hosp Almanzor Aguinaga Asenjo, Serv Anestesiol, Chiclayo, Peru
[4] Univ Senor Sipan, Pimentel, Peru
[5] Univ Tecnol Peru, Dept Ciencias, Chiclayo, Peru
[6] Univ Nacl Pedro Ruiz Gallo, Fac Ciencias Fisicas & Matemat, Lambayeque, Peru
关键词
Intensive Care Units; Vaccines; COVID-19; Critical care;
D O I
10.35434/rcmhnaaa.2022.154.1568
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vaccination against COVID-19 has been shown to reduce the risk of morbidity and mortality in the severe form of COVID and hospitalization in susceptible patients. Objective: To determine if there is a relationship between the number of doses of vaccine applied against COVID-19 and the recovery of the patient treated in the ICU of EsSalud-Lambayeque Contingency Hospitals between December 2021 and February 2022. Materials and methods: A descriptive study was proposed., transversal, correlational and retrospective; in a sample of 94 patients hospitalized in the ICU of the Luis Heysen Inchaustegui and Almanzor Aguinaga Asenjo Hospitals, randomly selected. Using a data collection form validated by experts, information was obtained from the medical records of the institutional computer network, maintaining confidentiality and ethical standards. For the analysis, percentages, frequencies and Chi Square were used for the relationship of categorical variables. Results: 60.64% were found to be male, average age 64.38 +/-13.65 years, 53.19% had one comorbidity, 21.27% had two or more, highlighting Arterial Hypertension and Diabetes Mellitus.. 35.11% did not have vaccines, 34.04% second dose, 23.40% third dose and 7.45% first dose. In the ICU discharge condition, 43.62% recovered. The recovery of the patient with the first dose was 57.14% (p<0.008), second dose in 65.63% (p<0.00002) and third dose 50% (p<0.003) Conclusions: If there is a significant relationship between the number of doses of the COVID-19 vaccine and the recovery of the patient in the ICU, a higher prevalence of males, older adults and comorbidities such as arterial hypertension and diabetes mellitus.
引用
收藏
页码:503 / 507
页数:11
相关论文
共 16 条
  • [1] Disparities in COVID-19 Vaccine Booster Uptake in the USA: December 2021–February 2022
    Adam Gaffney
    David U. Himmelstein
    Danny McCormick
    Steffie Woolhandler
    Journal of General Internal Medicine, 2022, 37 : 2918 - 2921
  • [2] Disparities in COVID-19 Vaccine Booster Uptake in the USA: December 2021-February 2022
    Gaffney, Adam
    Himmelstein, David U.
    McCormick, Danny
    Woolhandler, Steffie
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (11) : 2918 - 2921
  • [3] A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
    Guibert, Nicolas
    Trepat, Kylian
    Pozzetto, Bruno
    Josset, Laurence
    Allatif, Omran
    Saker, Kahina
    Brengel-Pesce, Karen
    Walzer, Thierry
    Vanhems, Philippe
    Trouillet-Assant, Sophie
    EUROSURVEILLANCE, 2023, 28 (15)
  • [4] Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022
    Lewis, Nathaniel M.
    Murray, Nancy
    Adams, Katherine
    Surie, Diya
    Gaglani, Manjusha
    Ginde, Adit A.
    McNeal, Tresa
    Ghamande, Shekhar
    Douin, David J.
    Talbot, H. Keipp
    Casey, Jonathan D.
    Mohr, Nicholas M.
    Zepeski, Anne
    Shapiro, Nathan, I
    Gibbs, Kevin W.
    Files, D. Clark
    Hager, David N.
    Ali, Harith
    Prekker, Matthew E.
    Frosch, Anne E.
    Exline, Matthew C.
    Gong, Michelle N.
    Mohamed, Amira
    Johnson, Nicholas J.
    Srinivasan, Vasisht
    Steingrub, Jay S.
    Peltan, Ithan D.
    Brown, Samuel M.
    Martin, Emily T.
    Monto, Arnold S.
    Lauring, Adam S.
    Khan, Akram
    Hough, Catherine L.
    Busse, Laurence W.
    Bender, William
    Duggal, Abhijit
    Wilson, Jennifer G.
    Gordon, Alexandra June
    Qadir, Nida
    Chang, Steven Y.
    Mallow, Christopher
    Rivas, Carolina
    Babcock, Hilary M.
    Kwon, Jennie H.
    Chappell, James D.
    Halasa, Natasha
    Grijalva, Carlos G.
    Rice, Todd W.
    Stubblefield, William B.
    Baughman, Adrienne
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):
  • [5] Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
    Castillo, Milena Suarez
    Khaoua, Hamid
    Courtejoie, Noemie
    EUROSURVEILLANCE, 2022, 27 (16)
  • [6] Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022 (vol 10, ofac698,2023)
    Lewis, Nathaniel M.
    Murray, Nancy
    Adams, Katherine
    Surie, Diya
    Gaglani, Manjusha
    Ginde, Adit A.
    McNeal, Tresa
    Ghamande, Shekhar
    Douin, David J.
    Talbot, H. Keipp
    Casey, Jonathan D.
    Mohr, Nicholas M.
    Zepeski, Anne
    Shapiro, Nathan, I
    Gibbs, Kevin W.
    Files, D. Clark
    Hager, David N.
    Ali, Harith
    Prekker, Matthew E.
    Frosch, Anne E.
    Exline, Matthew C.
    Gong, Michelle N.
    Mohamed, Amira
    Johnson, Nicholas J.
    Srinivasan, Vasisht
    Steingrub, Jay S.
    Peltan, Ithan D.
    Brown, Samuel M.
    Martin, Emily T.
    Monto, Arnold S.
    Lauring, Adam S.
    Khan, Akram
    Hough, Catherine L.
    Busse, Laurence W.
    Bender, William
    Duggal, Abhijit
    Wilson, Jennifer G.
    Gordon, Alexandra June
    Qadir, Nida
    Chang, Steven Y.
    Mallow, Christopher
    Rivas, Carolina
    Babcock, Hilary M.
    Kwon, Jennie H.
    Chappell, James D.
    Halasa, Natasha
    Grijalva, Carlos G.
    Rice, Todd W.
    Stubblefield, William B.
    Baughman, Adrienne
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
  • [7] Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years-United States, December 9, 2021-February 20, 2022
    Hause, Anne M.
    Baggs, James
    Marquez, Paige
    Abara, Winston E.
    Olubajo, Babatunde
    Myers, Tanya R.
    Su, John R.
    Thompson, Deborah
    Gee, Julianne
    Shimabukuro, Tom T.
    Shay, David K.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (09): : 347 - 351
  • [9] COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021
    Kriss, Jennifer L.
    Reynolds, Laura E.
    Wang, Alice
    Stokley, Shannon
    Cole, Matthew M.
    Harris, LaTreace Q.
    Shaw, Lauren K.
    Black, Carla L.
    Singleton, James A.
    Fitter, David L.
    Rose, Dale A.
    Ritchey, Matthew D.
    Toblin, Robin L.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (11): : 389 - 395
  • [10] Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022
    Kim, Sara S.
    Chung, Jessie R.
    Talbot, H. Keipp
    Grijalva, Carlos G.
    Wernli, Karen J.
    Kiniry, Erika
    Martin, Emily T.
    Monto, Arnold S.
    Belongia, Edward A.
    McLean, Huong Q.
    Gaglani, Manjusha
    Mamawala, Mufaddal
    Nowalk, Mary Patricia
    Geffel, Krissy Moehling
    Tartof, Sara Y.
    Florea, Ana
    Lee, Justin S.
    Tenforde, Mark W.
    Patel, Manish M.
    Flannery, Brendan
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (06) : 975 - 985